Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of open-label iptacopan in adults with primary IgA nephropathy who have completed earlier clinical trials CLNP023X2203 or CLNP023A2301. This Phase III rollover extension program allows participants to continue treatment while gathering additional data on the drugs effects over time. The study aims to assess the ongoing impact of iptacopan on disease progression until marketing authorization or other specified conditions are met. Participants receive iptacopan capsules at a dose of 200 mg taken orally twice daily. Treatment continues until one of several conditions occurs, including completion of 3 years from the last participants first visit, loss of benefit as judged by the investigator, a change in the drugs benefit-risk profile, need for dialysis or kidney transplant, or drug availability through commercial channels. This open-label design provides continuous access to iptacopan while monitoring long-term effects. During the study, participants undergo safety assessments including monitoring for adverse events, vital sign changes, ECG abnormalities, and laboratory test results from the first dose until 7 days after the last dose. Efficacy evaluations are conducted every 6 months to track kidney function and proteinuria levels. The total participation period may last up to three years, offering detailed data on the drugs long-term safety and clinical impact in primary IgA nephropathy.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease CKD and metabolic acidosis. This phase 3 study compares veverimer against a placebo to better understand its impact on these conditions. The study is sponsored by Renibus Therapeutics, Inc. and uses a randomized, double-blind, placebo-controlled design to ensure reliable results. Participants are randomly assigned to receive either 9 g of veverimer twice daily or a placebo twice daily. The study lasts up to 168 days, during which the effects of the treatments on serum bicarbonate levels and physical performance, specifically the Sit-to-Stand 5 times test, are assessed. The trial also monitors safety and tolerability through treatment-emergent adverse events throughout the study period. During the study, participants will have regular visits from screening through Day 168 where various assessments take place. These include measuring serum bicarbonate concentration, physical performance tests, frailty and muscle mass evaluations, and safety checks. Participants are expected to maintain consistent dietary habits and stable doses of any oral alkali therapies during the trial. The total length of participation extends through the 168-day treatment and evaluation period.
Actively Recruiting
Researchers are evaluating the impact of iptacopan treatment on adult patients with Immunoglobulin A Nephropathy IgAN. This study focuses on changes in kidney tissue and immune system markers related to the disease and aims to better understand the treatments effects on both systemic and kidney-specific aspects of IgAN. The trial is designed as a Phase 2, open-label, single-group study led by Novartis Pharmaceuticals. Participants will undergo a screening period followed by a baseline kidney biopsy. Eligible individuals receive iptacopan 200 mg twice daily orally for a 9-month treatment period without dose adjustments. At the end of treatment, a follow-up kidney biopsy is conducted to assess changes. Throughout the study, participants remain on their maximum tolerated or locally approved doses of ACE inhibitors or angiotensin receptor blockers. During the trial, participants will have kidney biopsies at baseline and at 9 months to evaluate complement activation and other markers of kidney function and disease progression. Researchers will monitor clinical and molecular biomarkers, including mesangial C3c deposition and CD68 cells. The study measures the proportion of participants achieving significant reductions in complement deposits, alongside changes in immunoglobulin staining. The total participation time extends through the 9-month treatment and follow-up biopsy.